Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QNRX Quoin Pharmaceuticals

Market Closed 03-13 16:00:00 EDT

8.06

-0.03

-0.37%

盘后8.06

+0.000.00%

16:10 EDT

High8.32	Low7.88	Vol10.27K
Open8.02	D1 Closing8.09	Amplitude5.44%
Mkt Cap13.03M	Tradable Cap9.55M	Total Shares1.62M
T/O83.35K	T/O Rate0.87%	Tradable Shares1.18M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QNRX","market":"US","secType":"STK","nameCN":"Quoin Pharmaceuticals","latestPrice":8.06,"timestamp":1773432000000,"preClose":8.09,"halted":0,"volume":10266,"hourTrading":{"tag":"盘后","latestPrice":8.06,"preClose":8.06,"latestTime":"16:10 EDT","volume":2,"amount":16.57,"timestamp":1773432605282,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.003708281829418957,"floatShares":1184400,"shares":1616200,"eps":-28.386957,"marketStatus":"Market Closed","change":-0.03,"latestTime":"03-13 16:00:00 EDT","open":8.0237,"high":8.32,"low":7.88,"amount":83350.5601,"amplitude":0.054388,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-28.386957,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1773648000000},"marketStatusCode":7,"adr":0,"adrRate":35,"exchange":"NASDAQ","adjPreClose":8.09,"preHourTrading":{"tag":"盘前","latestPrice":8.24,"preClose":8.09,"latestTime":"08:24 EDT","volume":210,"amount":1758.67986,"timestamp":1773404662092,"change":0.15,"changeRate":0.018541,"amplitude":0.076638},"postHourTrading":{"tag":"盘后","latestPrice":8.06,"preClose":8.06,"latestTime":"16:10 EDT","volume":2,"amount":16.57,"timestamp":1773432605282,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.4538943135979794},"requestUrl":"/m/hq/s/QNRX","defaultTab":"news","newsList":[{"id":"2618976323","title":"Quoin Pharmaceuticals begins two late-stage whole-body trials of QRX003 4% lotion for Netherton Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2618976323","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618976323?lang=en_us&edition=fundamental","pubTime":"2026-03-12 04:57","pubTimestamp":1773262667,"startTime":"0","endTime":"0","summary":"Quoin said the FDA granted Fast Track designation to QRX003 lotion (4%) for treating Netherton syndrome. QRX003 is being evaluated in two late-stage whole-body clinical trials designed to assess safety and efficacy in patients with Netherton syndrome. The company did not report clinical results in the announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL9qkBHG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"gpt_icon":0},{"id":"2618947659","title":"Quoin Pharmaceuticals receives U.S. Fast Track Designation to QRX003","url":"https://stock-news.laohu8.com/highlight/detail?id=2618947659","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618947659?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:38","pubTimestamp":1773232725,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (QNRX) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to QRX003 lotion for the treat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-receives-u-s-fast-track-designation-to-qrx003-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-receives-u-s-fast-track-designation-to-qrx003-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","QNRX"],"gpt_icon":0},{"id":"2618748942","title":"FDA grants Fast Track designation to Quoin's QRX003 for Netherton syndrome treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2618748942","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618748942?lang=en_us&edition=fundamental","pubTime":"2026-03-11 20:30","pubTimestamp":1773232223,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals said the U.S. FDA granted Fast Track designation to its QRX003 lotion (4%) for Netherton Syndrome, a regulatory status intended to speed development and potentially accelerate review. The company noted QRX003 previously received FDA Pediatric Rare Disease and Orphan Drug designations, and EMA Orphan Drug designation, which can provide incentives such as market exclusivity upon approval, tax credits and fee reductions.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL2NZgz0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4585","LU2210149790.SGD","BK4112","LU2210150020.SGD","LU2095319765.USD","SG9999014005.SGD","LU0314104364.USD","BK4588","QNRX","SG9999014013.SGD","IE00B3QW5Z07.USD","NDAQ","SG9999014021.USD","SG9999014039.USD","BK4139","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2618626560","title":"Quoin Pharmaceuticals Ltd  expected to post a loss of $3.34 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2618626560","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618626560?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:34","pubTimestamp":1773059650,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd  expected to post a loss of $3.34 a share - Earnings Preview Quoin Pharmaceuticals Ltd QNRX.OQ, QNRX.O is expected to  show no change in quarterly revenue when it reports  re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL8N3ZX13Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"gpt_icon":0},{"id":"2614403490","title":"Quoin Pharmaceuticals highlights continued growth of NETHERTON NOW program","url":"https://stock-news.laohu8.com/highlight/detail?id=2614403490","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614403490?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:53","pubTimestamp":1772114033,"startTime":"0","endTime":"0","summary":"In recognition of Rare Disease Day 2026, Quoin Pharmaceuticals (QNRX) highlighted the continued growth of its NETHERTON NOW awareness campaign, whi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-highlights-continued-growth-of-netherton-now-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-highlights-continued-growth-of-netherton-now-program-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2381873111.SGD","LU0354030438.USD","LU1803068979.SGD","LU2125909593.SGD","LU0320765059.SGD","LU0823434740.USD","LU1974910355.USD","LU1923622291.USD","LU0158827781.USD","LU1267930730.SGD","LU2433249047.HKD","LU0353189763.USD","LU1951198990.SGD","LU1116320901.HKD","LU1989764748.USD","LU1551013425.SGD","LU0082616367.USD","LU0265550359.USD","BK4528","BK4613","BK4097","LU0081259029.USD","LU0708995401.HKD","LU2125909916.SGD","LU0889565833.HKD","BK4139","BK4566","LU0689472784.USD","LU2111349929.HKD","LU1951200564.SGD","LU1989764664.SGD","IE00BMPRXN33.USD","IE00B894F039.SGD","LU1988902786.USD","LU2089284900.SGD","BK4585","IE00B19Z9P08.USD","LU1923623000.USD","LU2023251221.USD","BK4543","LU2023250843.SGD","BK4588","LU1989772840.SGD","LU0719512351.SGD","LU1153585028.USD","LU0672654240.SGD","LU2106854487.HKD","LU2458330243.SGD","BK4503","LU2543165471.USD","LU2023250504.SGD","LU0823434583.USD","LU2286300806.USD","LU1923622614.USD","BK4608","BK4601","LU2089283258.USD","LU0354030511.USD","LU0109392836.USD","LU0158827948.USD","BK4534","LU2271345857.HKD","BK4607","LU0011850046.USD","IE00B19Z9Z06.USD","LU1064131342.USD","LU1917777945.USD","QNRX","LU2458330169.SGD","LU0820561909.HKD","BK4581","LU2264538146.SGD","LU2087625088.SGD","NOWL","IE00BZ9MQY76.HKD","LU1989772923.USD","LU2125909759.SGD","LU0348723411.USD","LU2125909247.SGD","LU0316494557.USD","LU1116320737.USD","LU0353189680.USD","LU0820561818.USD","LU1551013342.USD","LU0109391861.USD","LU1323610961.USD","LU2028103732.USD","LU0943347566.SGD","IE00BMPRXR70.SGD","LU0265550946.USD","BK4550","LU2063271972.USD"],"gpt_icon":0},{"id":"2614422210","title":"NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2614422210","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614422210?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:30","pubTimestamp":1772112600,"startTime":"0","endTime":"0","summary":"Videos on the NETHERTON NOW website have been viewed 2 million times with 24 million impressions. Patients, families, and clinicians share the reality of living with Netherton Syndrome, a rare genetic skin disease with no approved treatment, and the enduring hope for a cure","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/26/3245592/0/en/NETHERTON-NOW-Recognizes-Rare-Disease-Day-and-Highlights-Growing-Global-Awareness-of-Netherton-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109391861.USD","LU2381873111.SGD","LU0823434583.USD","LU1116320901.HKD","LU1951200564.SGD","LU1988902786.USD","LU1323610961.USD","BK4566","LU2125909916.SGD","NOWL","LU0348723411.USD","BK4608","ETH","BK4528","LU1917777945.USD","LU2286300806.USD","LU2089283258.USD","BK4581","LU0820561818.USD","IE00B894F039.SGD","LU0820561909.HKD","BK4550","QNRX","LU0011850046.USD","LU0353189763.USD","IE00BZ9MQY76.HKD","LU1923623000.USD","LU2271345857.HKD","BK4534","IE00B19Z9Z06.USD","LU0316494557.USD","LU2089284900.SGD","LU0354030438.USD","LU0320765059.SGD","LU1923622291.USD","BK4139","BK4503","LU1153585028.USD","LU2264538146.SGD","BK4601","LU1989772840.SGD","LU2125909593.SGD","LU0265550946.USD","LU0109392836.USD","LU1923622614.USD","IE00B19Z9P08.USD","LU2087625088.SGD","LU0353189680.USD","LU0689472784.USD","LU0082616367.USD","IE00BMPRXN33.USD","LU1551013342.USD","LU2028103732.USD","LU1974910355.USD","LU2023251221.USD","BK4613","BK4543","LU0158827948.USD","LU2125909247.SGD","LU2063271972.USD","BK4585","LU1803068979.SGD","LU1951198990.SGD","LU1551013425.SGD","LU0889565833.HKD","LU1989764664.SGD","LU2458330243.SGD","BK4607","LU0158827781.USD","LU2023250843.SGD","LU0708995401.HKD","LU2543165471.USD","LU0081259029.USD","LU0943347566.SGD","LU0265550359.USD","BK4588","LU0823434740.USD","LU1989772923.USD","LU1116320737.USD","LU2023250504.SGD","LU2458330169.SGD","LU2111349929.HKD","LU2106854487.HKD","LU1064131342.USD","LU1267930730.SGD","BK4097","IE00BMPRXR70.SGD","LU0672654240.SGD","LU2433249047.HKD","LU1989764748.USD","LU0719512351.SGD","LU2125909759.SGD","LU0354030511.USD"],"gpt_icon":0},{"id":"2612425463","title":"Quoin Pharmaceuticals Ltd – ADR trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2612425463","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612425463?lang=en_us&edition=fundamental","pubTime":"2026-02-17 23:15","pubTimestamp":1771341327,"startTime":"0","endTime":"0","summary":"10:11 EST Quoin Pharmaceuticals (QNRX) Ltd – ADR trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-ltd-adr-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-ltd-adr-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNRX","BK4139"],"gpt_icon":0},{"id":"2612446398","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:11 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2612446398","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612446398?lang=en_us&edition=fundamental","pubTime":"2026-02-17 23:11","pubTimestamp":1771341076,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 10:11 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nAQN2LMIDB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"gpt_icon":0},{"id":"2608926814","title":"Quoin Pharmaceuticals Files Initial Beneficial Ownership Statement for Stonepine Capital Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2608926814","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608926814?lang=en_us&edition=fundamental","pubTime":"2026-02-03 09:01","pubTimestamp":1770080483,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing identifies Stonepine Capital Management, LLC as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL20hFxM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Quoin Pharmaceuticals Files Initial Beneficial Ownership Statement for Stonepine Capital Management","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"gpt_icon":0},{"id":"2606731248","title":"Quoin Pharmaceuticals Submits QRX003 for Orphan Drug Designation and Fast Track Review in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2606731248","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606731248?lang=en_us&edition=fundamental","pubTime":"2026-01-28 01:44","pubTimestamp":1769535858,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd. announced that it has submitted an application for Orphan Drug Designation  for its lead product candidate, QRX003, for the treatment of Netherton Syndrome to the Japanese Ministry of Health, Labour and Welfare . The MHLW has confirmed that QRX003 qualifies for both Orphan Drug Designation and Fast Track regulatory review status in Japan. QRX003 previously received Orphan Drug Designation from the U.S. Food and Drug Administration and the European Medicines Agency in 2025. If granted in Japan, QRX003 will have ODD status in Quoin's key commercial territories of the US, EU, and Japan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nNDL9ZFPWQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BKPKM429.USD","LU0314104364.USD","LU2095319765.USD","IE00B3QW5Z07.USD","NDAQ","LU2210150020.SGD","BK4588","BK4112","QNRX","LU2210149790.SGD","SG9999014005.SGD","SG9999014039.USD","BK4585","SG9999014021.USD","BK4139","IE00BGHQF748.EUR","SG9999014013.SGD"],"gpt_icon":0},{"id":"2606787367","title":"Quoin announces submission to Japanese MHLW for ODD for QRX003","url":"https://stock-news.laohu8.com/highlight/detail?id=2606787367","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606787367?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:36","pubTimestamp":1769521010,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals (QNRX) announced that following a successful meeting with the Japanese MHLW that it has submitted an application for Orphan D...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-announces-submission-to-japanese-mhlw-for-odd-for-qrx003-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-announces-submission-to-japanese-mhlw-for-odd-for-qrx003-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009354923.USD","BK4183","QNRX","ODD","BK4139"],"gpt_icon":0},{"id":"2604115270","title":"Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application for QRX003 in Saudi Arabia","url":"https://stock-news.laohu8.com/highlight/detail?id=2604115270","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604115270?lang=en_us&edition=fundamental","pubTime":"2026-01-20 21:30","pubTimestamp":1768915828,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd. has filed an application for Breakthrough Medicine Designation with the Saudi Food and Drug Authority  for QRX003, its lead investigational topical product for the treatment of Netherton Syndrome. If the designation is granted, QRX003 could become the first approved treatment for Netherton Syndrome and may be available for sale and reimbursement in Saudi Arabia in the second half of 2026. QRX003 is currently being evaluated in two late-stage clinical trials, with enrollment expected to be completed in the first half of 2026 and top-line data anticipated in the second half of the year. Quoin also plans to submit a New Drug Application in the United States and other territories pending successful clinical outcomes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be int","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nNDL3CK6Kt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","LU2095319765.USD","LU0314104364.USD","IE00BKPKM429.USD","LU2210149790.SGD","QNRX","BK4112","SG9999014021.USD","NDAQ","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4139","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014039.USD","LU2210150020.SGD","BK4588"],"gpt_icon":0},{"id":"2589781062","title":"ADRs Close Lower; Quoin Pharmaceuticals Ltd. Declines 36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589781062","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589781062?lang=en_us&edition=fundamental","pubTime":"2025-12-06 05:30","pubTimestamp":1764970200,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.International stocks trading in New York closed lower on Friday, as the S&P/BNY Mellon index of American depositary receipts declined 0.3% to 232.31.The European index dropped 0.5% to 204.74. The Asian index gained 0.4% to 310.61. The Latin American index fell 4.2% to 234.96, while the emerging-markets index was flat at 518.38.Quoin Pharmaceuticals Ltd., based in Israel, posted the largest decline, cratering 36% to $12.09, followed by shares of China's Adlai Nortye Ltd., which tumbled 16% to $1.01. Shares of China-based Akso Health Group tumbled 11% to $1.39.China's PomDoctor Ltd. was the biggest leader during the session, jumping 15% to $5.45, and Israel-based SaverOne 2014 Ltd. surged 13% to $1.07. Concord Medical Services Holdings Ltd., which is based in China, rounded out the top three leaders on Friday, with shares surging 13% to $3.99.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"gpt_icon":0},{"id":"2589489208","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2589489208","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589489208?lang=en_us&edition=fundamental","pubTime":"2025-12-05 20:55","pubTimestamp":1764939318,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals  shares were 19% lower pre-bell Friday after a 6.1% increase in the previous session.Polyrizon  stock was down 17%, paring Thursday's rally.Domo  shares were 14% lower after the company reported late Thursday lower fiscal Q3 revenue.Parsons  stock was down 14% after a 1.9% gain in the previous session.Argan  shares were 11% lower, a day after the company posted lower fiscal Q3 revenue.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4129","LU1559883803.SGD","PSN","DOMO","BK4123","LU2065731478.USD","QNRX","BK4023","BK4187","LU0566484027.USD","PLRZ","AGX","BK4139"],"gpt_icon":1},{"id":"2584670874","title":"Quoin Pharmaceuticals Approves New Stock Option Agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2584670874","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584670874?lang=en_us&edition=fundamental","pubTime":"2025-11-18 06:34","pubTimestamp":1763418874,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals ( ($QNRX) ) has shared an update. On November 14, 2025, Quoin Pharmaceuticals‘ Board of Directors approved new award agreemen...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/quoin-pharmaceuticals-approves-new-stock-option-agreements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/quoin-pharmaceuticals-approves-new-stock-option-agreements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","QNRX"],"gpt_icon":0},{"id":"2584167240","title":"Quoin Pharmaceuticals Unveils New Equity Incentive Plan for Executives and Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2584167240","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584167240?lang=en_us&edition=fundamental","pubTime":"2025-11-18 06:01","pubTimestamp":1763416895,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd. has approved new forms of stock option award agreements for directors and executive officers under its 2025 Equity Incentive Plan. The updated agreements allow options to be exercised through various payment methods, including cash, check, wire transfer, and cashless exercise mechanisms. In the event of termination, unvested awards will be forfeited immediately. Vested awards may be exercised for up to one year after death or disability, or up to three months after termination for reasons other than death, disability, or cause. All awards, whether vested or unvested, will be forfeited immediately upon termination for cause.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL8BpCPj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX"],"gpt_icon":0},{"id":"2582374169","title":"Quoin Pharmaceuticals Achieves Key Milestone in Rapamycin Delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=2582374169","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582374169?lang=en_us&edition=fundamental","pubTime":"2025-11-12 21:37","pubTimestamp":1762954664,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals ( ($QNRX) ) just unveiled an update. On November 11, 2025, Quoin Pharmaceuticals announced the successful achievement of targ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/quoin-pharmaceuticals-achieves-key-milestone-in-rapamycin-delivery?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/quoin-pharmaceuticals-achieves-key-milestone-in-rapamycin-delivery?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","QNRX"],"gpt_icon":0},{"id":"2582736485","title":"Quoin Pharmaceuticals Achieves Target Rapamycin Loadings in Topical Delivery Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2582736485","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582736485?lang=en_us&edition=fundamental","pubTime":"2025-11-11 21:31","pubTimestamp":1762867871,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd. has announced the successful achievement of target loading concentrations for its two proprietary topical rapamycin delivery technologies. The company has formulated a topical lotion with a 4% w/w rapamycin concentration and a dermal patch system with a 5% w/w concentration. These developments mark a significant milestone for Quoin's topical rapamycin programs. The company plans to begin manufacturing clinical trial and stability batches in the fourth quarter of 2025, with clinical testing set to commence in the first half of 2026. Initial clinical indications will include Microcystic Lymphatic Malformations and Venous Malformations, for which no FDA-approved treatments currently exist. The results have been announced by the company and clinical testing will be conducted in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nNDL3QV5M2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNRX","BK4139"],"gpt_icon":0},{"id":"2581144092","title":"Quoin Pharmaceuticals Ltd reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2581144092","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581144092?lang=en_us&edition=fundamental","pubTime":"2025-11-06 23:07","pubTimestamp":1762441625,"startTime":"0","endTime":"0","summary":"Quoin Pharmaceuticals Ltd reports results for the quarter ended September 30 - Earnings SummaryQuoin Pharmaceuticals Ltd QNRX.OQ reported a quarterly adjusted loss of $6.71 per share for the quarter e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL8N3WI2JB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNRX"],"gpt_icon":0},{"id":"2581929096","title":"Quoin Pharmaceuticals reports Q3 EPS ($6.71) vs. ($16.29) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2581929096","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581929096?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:36","pubTimestamp":1762436163,"startTime":"0","endTime":"0","summary":"“The third quarter of 2025 has been a period of significant momentum and strategic advancement for Quoin Pharmaceuticals (QNRX),” said Dr. Michael ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-reports-q3-eps-6-71-vs-16-29-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quoin-pharmaceuticals-reports-q3-eps-6-71-vs-16-29-last-year-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.quoinpharma.com","stockEarnings":[{"period":"1week","weight":-0.0704},{"period":"1month","weight":0.005},{"period":"3month","weight":-0.2175},{"period":"6month","weight":0.0605},{"period":"1year","weight":-0.2194},{"period":"ytd","weight":-0.4414}],"compareEarnings":[{"period":"1week","weight":-0.015},{"period":"1month","weight":-0.0429},{"period":"3month","weight":-0.0286},{"period":"6month","weight":0.0074},{"period":"1year","weight":0.2011},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. operates as a subsidiary of Skinvisible, Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.264124},{"month":2,"riseRate":0.2,"avgChangeRate":-0.199382},{"month":3,"riseRate":0.2,"avgChangeRate":-0.187559},{"month":4,"riseRate":0.25,"avgChangeRate":-0.184354},{"month":5,"riseRate":0.5,"avgChangeRate":0.000391},{"month":6,"riseRate":0.5,"avgChangeRate":-0.071654},{"month":7,"riseRate":0.5,"avgChangeRate":-0.033987},{"month":8,"riseRate":0.5,"avgChangeRate":-0.098098},{"month":9,"riseRate":0,"avgChangeRate":-0.208503},{"month":10,"riseRate":0.5,"avgChangeRate":0.22434},{"month":11,"riseRate":0.4,"avgChangeRate":0.035616},{"month":12,"riseRate":0.2,"avgChangeRate":-0.187047}],"exchange":"NASDAQ","name":"Quoin Pharmaceuticals","nameEN":"Quoin Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Quoin Pharmaceuticals(QNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Quoin Pharmaceuticals,QNRX,Quoin Pharmaceuticals股票,Quoin Pharmaceuticals股票老虎,Quoin Pharmaceuticals股票老虎国际,Quoin Pharmaceuticals行情,Quoin Pharmaceuticals股票行情,Quoin Pharmaceuticals股价,Quoin Pharmaceuticals股市,Quoin Pharmaceuticals股票价格,Quoin Pharmaceuticals股票交易,Quoin Pharmaceuticals股票购买,Quoin Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Quoin Pharmaceuticals(QNRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Quoin Pharmaceuticals(QNRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction